Key result
Transcatheter implantation of an atrial flow regulator device in three children with restrictive cardiomyopathy was feasible and led to marked clinical and hemodynamic improvements.
Why the study?
Restrictive cardiomyopathy has a poor prognosis with limited treatment options apart from heart transplantation.
Does interventional atrial flow regulator (AFR) implantation improve clinical and hemodynamic outcomes in children with restrictive cardiomyopathy?
Case Report (n=3)
Yes
Does interventional atrial flow regulator (AFR) implantation improve clinical and hemodynamic outcomes in children with restrictive cardiomyopathy?
Atrial flow regulator implantation may serve as a bridge to heart transplantation or destination therapy in children with restrictive cardiomyopathy.
Supports AFR as potential bridge to transplant in pediatric restrictive cardiomyopathy; leaves open need for prospective trials.
Restrictive cardiomyopathy (RCM) has a poor prognosis and limited treatment options apart from heart transplantation (HTx). We report on the first-in-human interventional atrial flow regulator (AFR) implantations in 3 children with RCM, leading to marked clinical and hemodynamic improvement. We propose the AFR as bridge to HTx or destination therapy in RCM. ( Level of Difficulty: Advanced. )
No takes yet. Share an insight, caveat, or question.
Hansmann et al. (2022) conducted a case report in Restrictive cardiomyopathy with postcapillary pulmonary hypertension (n=3). Atrial Flow Regulator (AFR) device vs. Baseline (pre-implantation) was evaluated on Hemodynamic and clinical improvement (LA size, PAWP, NYHA class). Transcatheter implantation of an atrial flow regulator device in three children with restrictive cardiomyopathy was feasible and led to marked clinical and hemodynamic improvements.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: